Abstract
Background: Abnormal uterine bleeding is a clinically important but often overlooked concern during antithrombotic therapy, particularly in cardiovascular care where anticoagulant and antiplatelet regimens are used. Objective: To describe paired menstrual changes during cardiovascular antithrombotic therapy and to explore documented increased or prolonged bleeding across treatment classes and observed regimens. Methods: This prospective observational paired clinical follow-up study included 50 menstruating women aged 18–55 years with regular menses who received antithrombotic therapy for cardiovascular conditions. Source records specified monthly follow-up and at least 3 months of anticipated treatment. Primary outcomes were paired changes in menstrual-cycle category and menstrual duration; documented increased or prolonged bleeding and variation across observed regimens were secondary exploratory outcomes. Results: Abnormal menstrual-cycle categories increased from 8/50 (16.0%) to 14/50 (28.0%), and prolonged menses increased from 2/49 (4.1%) to 8/49 (16.3%); both exact McNemar P=0.031. Documented increased or prolonged bleeding was recorded in 17/46 evaluable participants (37.0%). Menstrual-related healthcare use or absence was more frequent among those with documented bleeding than among those without it (9/17 vs 4/29; Fisher P = 0.007). The proportion with documented bleeding varied across seven observed regimens (P=0.006) and was highest among rivaroxaban recipients (13/19, 68.4%). Conclusions: Menstrual changes and bleeding-related clinical burden were observed during follow-up in women receiving antithrombotic therapy for cardiovascular conditions. The proportion with documented bleeding varied across observed regimens and was highest among rivaroxaban recipients. Larger prospective studies using standardized menstrual outcome measures are needed to evaluate between-regimen differences.

This publication has 17 references indexed in Scilit: